ArticleApplied biochemistry and biotechnology2026
The Tumor-Promoting Role of ADM in Bladder Cancer and its Mediated Mechanisms of Cell Death via PKR and STAT1.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Adrenomedullin (ADM) is an endogenous physiological hormone that has also been identified as a tumor-associated cytokine. This study aims to explore whether ADM can impact on bladder cancer (BC) development, focusing on mechanisms of programmed cell death and relate to protein binding, thereby expanding its diagnostic value of clinical applications. Here we used ELISA and bladder cancer cell lines to detect ADM expression in clinical serum samples and investigate its functional roles. Quantitative PCR, Western blot, and flow cytometry analyses were integrated to evaluate the effects of ADM modulation on cell proliferation and apoptosis. Quantitative proteomics using tandem mass tag (TMT) labeling combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to profile alterations in protein expression following ADM knockdown in bladder cancer cells. The effect of ADM on cell membrane integrity was assessed using transmission electron microscopy (TEM) and lactate dehydrogenase (LDH) release assays. Furthermore, siRNA-based experiments combined with immunoprecipitation were employed to investigate protein-protein interactions within bladder cancer (BC) cells. Finally, a mouse xenograft model was established to observe tumor growth and progression. Knocking down ADM increases apoptosis and decreases proliferation, while overexpressing ADM reverses these outcomes. Inhibition of ADM-induced LDH release and necroptosis-like cellular changes, observed using TEM, indicates the prevention of cell membrane rupture. Furthermore, ADM activates the PI3K/AKT pathway to phosphorylate STAT1, inhibiting its nuclear translocation; concurrently, ADM directly binds to STAT1 to block its activation. ADM knockdown reverses these dual inhibitory effects, upregulating the STAT1-PKR axis and activating the RIPK1/RIPK3/MLKL cascade to induce necroptosis. In addition, Animal experiments demonstrated a reduction in tumor growth in mice with ADM knockdown. Our study elucidated the novel tumorigenic role and specific mechanism of ADM in bladder cancer, providing new therapeutic insights for its prevention and treatment.
Indexed as
Identifiers
41979740What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.